Open Access

Severe intellectual disability, omphalocele, hypospadia and high blood pressure associated to a deletion at 2q22.1q22.3: case report

  • Milene Vianna Mulatinho1,
  • Cassio Luiz de Carvalho Serao2,
  • Fernanda Scalco3,
  • David Hardekopf4,
  • Sona Pekova4,
  • Kristin Mrasek5,
  • Thomas Liehr5,
  • Anja Weise5,
  • Nagesh Rao6 and
  • Juan Clinton LlerenaJr1Email author
Molecular Cytogenetics20125:30

DOI: 10.1186/1755-8166-5-30

Received: 4 March 2012

Accepted: 11 June 2012

Published: 11 June 2012

Abstract

Background

Recently, array-comparative genomic hybridization (aCGH) platforms have significantly improved the resolution of chromosomal analysis allowing the identification of genomic copy number gains and losses smaller than 5 Mb. Here we report on a young man with unexplained severe mental retardation, autism spectrum disorder, congenital malformations comprising hypospadia and omphalocele, and episodes of high blood pressure. An ~ 6 Mb interstitial deletion that includes the causative genes is identified by oligonucleotide-based aCGH.

Results

Our index case exhibited a de novo chromosomal abnormality at 2q22 [del(2)(q22.1q22.3)dn] which was not visible at the 550 haploid band level. The deleted region includes eight genes: HNMT, SPOPL, NXPH2, LOC64702, LRP1B, KYNU, ARHGAP15 and GTDC1.

Discussion

aCGH revealed an ~ 6 Mb deletion in 2q22.1 to 2q22.3 in an as-yet unique clinical case associated with intellectual disability, congenital malformations and autism spectrum disorder. Interestingly, the deletion is co-localized with a fragile site (FRA2K), which could be involved in the formation of this chromosomal aberration. Further studies are needed to determine if deletions of 2q22.1 to 2q22.3 define a new microdeletion syndrome.

Keywords

Array-comparative genomic hybridization (aCGH) Fluorescence in situ hybridization (FISH) 2q22 deletion syndrome Birth defects Hypospadia omphalocele Severe mental retardation Essential hypertension High blood pressure

Introduction

Intellectual disability (ID) or Mental Retardation (MR) affects a large number of individuals, and was recently estimated to have a prevalence of 1% in the general population [1]. Chromosomal abnormalities are causative factors in 4% to 34.1% of cases, detected mainly by G-band-based banding studies [2, 3]. The advent of array-comparative genomic hybridization (aCGH) has increased the detection rate by an additional 15–20% [4], generally by identifying submicroscopic chromosomal abnormalities. This progress has enabled a refined association of chromosomal aberrations and potentially underlying disease-causing genes, leading to better karyotype/genotype-phenotype correlations, and more qualified genetic counseling for families [58].

Genes associated with ID/MR can be found distributed throughout the human genome. According to the OMIM database [9] six genetic syndromes have been assigned to chromosomal region 2q22 to 2q23, including, Mowat-Wilson Syndrome (MWS) (MIM:235730); Nemaline Myopathy 2 (MIM:256030); Meier-Gorlin Syndrome 2 (MIM:613800); Susceptibility to Asthma (MIM:600807); Idiopathic Generalized Epilepsy 9 (MIM:607682); and, Hypogonadism, Alopecia, Diabetes Mellitus, Mental Retardation and Extrapyramidal Signs syndrome (MIM:241080). MWS is the best known disease in 2q22 ~ q23, presenting multiple congenital anomalies including Hirschsprung disease (HD) (MIM:142623) and MR. It has been recently associated with truncating mutations and/or heterozygous deletions of the ZEB2 homeobox gene (ZFHX1B) [1013].

Here we present a Brazilian patient carrying a hitherto unreported ~ 6 Mb microdeletion in 2q22.1 to 2q22.3 upstream and outside the ZEB2 region [14]. The patient’s phenotype comprises severe autism spectrum disorder, associated to ID/MR, and congenital malformations, such as, omphalocele and hypospadia with cryptorchidism. Episodes of essential hypertension were an important feature in adolescence and were controlled with specific anti-hypertensive agents.

Case presentation

The patient is the only son of a young non-consanguineous couple, without any familial history. He was born at term by cesarean section; weight 3.950 g (>P50th percentile); length 51 cm (50th percentile). The patient had his first genetic evaluation at 4 years of age, being referred due to global developmental delay, lack of speech, an omphalocele (corrected by surgery), and balanic hypospadia with bilateral cryptorchidism. At physical examination he presented a coarse face with deep-set eyes, thick eyebrows, protruding tongue, small teeth, pointed chin, bulbous nose, wide spaced and hypoplastic nipples, scoliosis, corrected balanic hypospadia with a flattened gland, bilateral clinodactyly of the fifth finger, non-specific dermatoglyphic pattern, global developmental delay and behavioral disorder. A neurological evaluation through the Childhood Autism Rating Scale (CARS) protocol revealed a score of 44.5, compatible with an autism spectrum disorder.

Clinical follow-up proceeded on different occasions, and a series of hypertension episodes were detected when the patient was 17 years old, ranging from 150x100 mm Hg to 140x80 mm Hg. His body mass index (BMI) was 40 kg/m2, without any echocardiogram or electrocardiogram disturbance. Complete blood count, cranial cerebral tomography, thyroid hormones and biochemical evaluation were all normal, except for high triglycerides (289 mg/dl [normal values: 50–200 mg/dl]). He was treated with an angiotensin-converting enzyme inhibitor (captopril 25 mg daily) and dietetic measures, losing more than 40 kg in 2 years.

Recently, a new clinical evaluation was performed. He is currently 23 years old and presents in good physical health, with a BMI of 27.5 kg/m2 and normalization of his blood pressure without the use of antihypertensive drugs. He still suffers from a severe behavioral disorder, occasional tantrums, stereotyped movements of his trunk and repetitive whistling. Such clinical signs have improved dramatically with the use of antipsychotic drugs. Differential diagnoses such as Smith-Magenis, Simpson-Golabi-Behmel and Beckwith-Wiedemann syndromes have been ruled.

Results

In the current case, G-banding and subtelomeric screening as well as molecular testing for the FMR1 and FMR2 genes were all normal (data not shown). aCGH identified an interstitial deletion of 6 Mb in the long arm of chromosome from 2q22.1 to 2q22.3, spanning positions 138,750,000 to 144,750,000 (Figure 1) and comprising eight genes (Table 1) [14]. The molecular cytogenetic karyotype according to ISCN 2009 was designated as: arr 2q22.1q22.3(138,750,000–144,750,000)x1. Seven out of 10 FISH probes used in the 2q22.1 band confirmed the deletion (Table 2). Eight to fourteen metaphase spreads were evaluated (Figure 2). The absence of xanthurenic acid in the patient’s urine showed that the metabolic pathway of tryptophan was not altered.
https://static-content.springer.com/image/art%3A10.1186%2F1755-8166-5-30/MediaObjects/13039_2012_Article_130_Fig1_HTML.jpg
Figure 1

NimbleGen whole-genome oligonucleotide aCGH profile for chromosome 2q. The ideogram (grey bars) depicts 2q22.1 to 2q22.3 genomic regions with the cytogenetic bands on the long arm of chromosome 2 (not on scale). The ~ 6 Mb interstitial deletion interval at 2q22.1–q22.3 [hg19, chr2: 138,750,000–144,750,000 bp] is indicated by a red horizontal line below zero and the two black dotted vertical lines.

Table 1

Genes within the 2q22.1 to 2q22.3 deleted region according to OMIM[9]

gene symbol

name

OMIM #

description

function

HNMT

NM_006895

605238

Homo sapiens histamine N-methyltransferase (HNMT), transcript variant 1.

It metabolizes Histamine in mammals. This gene encodes the first enzyme, which is found in the cytosol and uses S-adenosyl-L-methionine as the methyl donor. This variant (1) represents the longest transcript and it encodes the longest protein (isoform 1).

SPOPL

NM_001001664

 

Homo sapiens speckle-type POZ protein-like (SPOPL), mRNA

-

NXPH2

NM_007226

604635

Homo sapiens neurexophilin 2 (NXPH2), m RNA.

-

LOC647012

NR_033658

 

Homo sapiens YY1 transcription factor pseudogene (LOC647012), non-coding RNA.

-

LRP1B

NM_018557

608766

LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1B

LRP1B belongs to the low density lipoprotein (LDL) receptor gene family. These receptors play a wide variety of roles in normal cell function and development due to their interactions with multiple ligands.

KYNU

NM_001032998; NM_003937

605197

Homo sapiens kynureninase (KYNU)

Kynureninase is a pyridoxal-5'-phosphate (pyridoxal-P) dependent enzyme that catalyzes the cleavage of L-kynurenine and L-3-hydroxykynurenine into anthranilic and 3-hydroxyanthranilic acids, respectively. Kynureninase is involved in the biosynthesis of NAD cofactors from tryptophan through the kynurenine pathway. Alternative splicing results in multiple transcript variants.

ARHGAP15

NM_018460

610578

Homo sapiens Rho GTPase activating protein 15 (ARHGAP15), mRNA

RHO GTPases (see ARHA; MIM 165390) regulate diverse biologic processes, and their activity is regulated by RHO GTPase-activating proteins (GAPs), such as ARHGAP15

GTDC1

NM_018460; NM_024659; NM_001006636

61065

Homo sapiens glycosyltransferase-like domain containing 1 (GTDC1)

GTDC1 is ubiquitous expressed at relatively high levels in lung, spleen, testis, and peripheral blood leukocytes, suggesting that it may have biochemical functions in these organs.

Table 2

FISH probes used inside the 2q22.1-2q22.3 region to confirm the array data[15, 16]

Locus

signals

BACs

Accession number

Start position (bp)

End position (bp)

2q22.1

2x

RP11-112 N16

AC010873

137,567,308

137,747,509

2q22.1

del

RP11-731 F1

AC069394.6

138,791,256

138,964,607

2q22.1

del

RP11-597P14

AC097523

138,954,985

139,129,617

2q22.1

del

RP11-231E19

AC092620.2

139,299,060

139,450,096

2q22.1

del

RP11-137 J9

AC092837

139,462,901

139,629,396

2q22.1

del

RP11-432O12

AC023468

139,608,867

139,779,582

2q22.1

del

RP11-15D9

AC109345

139,736,474

139,903,043

2q22.1

del

RP11-164E7

AC108036

141,266,879

141,423,790

2q22.3

2x

RP11-64O2

AQ237761 AQ237759

145,181,324

145,355,222

2q23.3

2x

RP11-58 K7

AQ201454 AQ201457

153,589,449

153,743,069

https://static-content.springer.com/image/art%3A10.1186%2F1755-8166-5-30/MediaObjects/13039_2012_Article_130_Fig2_HTML.jpg
Figure 2

Three pairs of chromosome 2 are shown to illustrate the FISH results obtained with the BAC probes. a) RP11–587 K7 in 2q23.3 (green) and RP11–112 N16 in 2q22.1 (red) were located outside the deleted region. b) RP11–64O2 in 2q22.3 (green) is located outside the deleted region, while RP11–731 F1 in 2q22.1 (red) is within the affected region. c) RP11–137 J9 (green) and RP11–164E7 (red) both are missing on the derivative chromosome 2, indicating deletions in 2q22.1.

Human Genome Assembly Build 37 (hg19) shows that the region 2q22.1 to 2q22.3 is covered by small copy number variations, inversions (structural variations) and InDels, but no sequence gaps.

Discussion

A 23-year-old patient with ID/MR, autism, essential hypertension, and congenital malformations including an omphalocele and hypospadias with cryptorchidism is reported. He carries an ~6 Mb de novo microdeletion at 2q22.1–22.3 identified by an oligonucleotide aCGH panel [arr 2q22.1q22.3(138,750,000–144,750,000)x1 dn] according to Human Genome Assembly Build 37 (hg19).

Table 3 summarizes the clinical and genomic data from our index case and four patients described in the Decipher database with overlapping deletion intervals (138,750,000 to 144,750,000 bp) [17]. ID/MR is a common clinical feature, but none of the other listed cases presented with congenital malformations such as those found in our patient. Besides ID/MR, two patients show other common clinical features: strabismus and thick eyebrows (Patient 2566); and strabismus, bulbous nasal tip, and hypoplastic/inverted/absent nipples (Patient 1607). Interestingly, Patient 1607 has a complex karyotype involving chromosomes 2, 3 and 5 [18]. None of the individuals listed in Table 3 shared the exact breakpoints at 2q22.1–q22.3 as observed in our patient [17].
Table 3

Present case and four patients listed at Decipher with similar deletions, ranging from 2q22.1 to 2q22.3, are shown

Patient

Cytogenetic deletion

sex

Interval start-end (bp, hg19)

Interval (Mb)

RefSeq Gene

Phenotype

This report

2q22.1q22.3

Male

138,750,000–144,750,000

6

HNMT, SPOPL, NXPH2, LOC647012, LRP1B, KYNU, ARHGAP15, GTDC1

Omphalocele, cryptorchidism, hypospadia. ID/MR, deep-set eyes, strabismus, thick eyebrow, protruding tongue, small teeth, pointed chin, bulbous nose, wide spaced nipples, hypoplastic nipples, bilateral clinodactyly of fifth finger, non-specific dermatoglyphic patterns, scoliosis, global developmental delay and behavioral disorder. Autism spectrum disorder.

1607

2q22.1q22.3

Female

139,813,180–145,063,389

5,25

HNMT, SPOPL, NXPH2, LRP1B, KYNU, ARHGAP15, GTDC1

ID/MR, strabismus, bulbous nasal tip, hypoplastic/inverted/absent nipples.

2566

2q22.2q22.3

Female

143,635,233–147,935,002

4,30

LRP1B, KYNU, ARHGAP15, GTDC1

ID/MR, strabismus, thick eyebrows.

250662

2q22.1q22.3

Male

141,232,786–147,935,002

6,70

HNMT, SPOPL, NXPH2, LRP1B, KYNU, ARHGAP15, GTDC1

251811

2q22.2q22.3

Female

143,715,235–146,369,069

2,65

LRP1B, KYNU, ARHGAP15, GTDC1

LEGEND: important data from five individuals with overlapping intervals are shown. The RefSeq genes and the phenotype columns list only the genes and the clinical findings shared with our patient. Full information of gene contents and phenotype from the Decipher patients is seen at Decipher website [17].

A child with MWS presenting with delayed psychomotor development, hypotonia, a variety of dysmorphic features, genitourinary anomalies and a severe course of HD has been described with a deletion at 2q22.2 to 2q22.3 [143,468,147–147,106,860] [19]. This 3.6 Mb aberration included ZEB2 and three other genes not currently associated with disease-KYNU, ARHGAP15 and GTDC1-all encoding for proteins involved in ubiquitous and non-specific pathways [2022]. This deletion segment overlaps with our case in an ~ 1.2 Mb [143,468,147–144,750,000] comprising KYNU, ARHGAP15 and GTDC1 (Table 1). The authors speculate that those genes could play a crucial role in the process of tissue regeneration [19]. While many candidate genes have been studied to investigate their role in birth defects such as omphalocele and hypospadias/cryptorchidism [2325], the clinical observations in our patient suggests the assignment of such malformations to the genes in the region 2q22.2–2q22.3.

Particularly interesting seems to be the function of the gene KYNU. It has previously been mentioned as possibly participating in a three-gene interaction influencing hypospadia, cryptorchidism and/or omphalocele [19]. However, a polymorphism in KYNU has also been linked to essential hypertension in a group of Han Chinese [26]. This feature has been investigated by studies that show the influence of KYNU as a candidate for hypertension in spontaneously hypertensive rats [27, 28]. KYNU encodes kynureninase, a vitamin B6-dependent enzyme involved in the kynurenine pathway for the biosynthesis of NAD cofactors from tryptophan, and its deficiency has been associated with abnormal tryptophan metabolism (MIM:605197) [22]. A massive urinary excretion of xanturenic acid known as hydroxykynureninuria or xanturenic aciduria (MIM:236800) can be detected in cases of kynureninase deficiency, due to defects in the kynurenine pathway [22, 29]. Based on the literature, an investigation was done to detect the presence of xanthurenic acid in our patient’s urine to examine the function of this gene. This biochemical study showed a normal level of xanthurenic acid, indicating that the tryptophan pathway is not affected and with a likely normal gene function. This result is in accordance with the low rank of 91.4% in the Decipher database, indicating that this gene is more likely to not exhibit haploinsufficiency [17]. Finally, genes and/or susceptibility loci on the long arm of chromosome 2 have been recently linked to blood pressure and hypertension by genome-wide association studies, such as STK39 at 2q24.3 [30]; PMS1 and MSTN, both at 2q32.2 [31]; DS2S2382 and DS2S338 at 2q35–q37 [32].

Within the region 2q22.1–2q22.3, no functions have yet been assigned to SPOPL, NXPH2 or LOC647012. HNMT is the only gene currently associated with human disease (Asthma) [9]. Our patient, however, has not shown any episodes of asthma. Special attention should be given to LRP1B, which is a newly identified member of the LDL receptor family. It was originally described as a putative tumor suppressor in lung cancer cells, but its expression profile in several regions of the adult human brain such as cortex, hippocampus and cerebellum suggests it may have additional functions in the central nervous system [3335]. Its interaction with the β-amyloid precursor protein could protect against the pathogenesis of Alzheimer’s disease [33]. Expression of this gene has also been reported in the thyroid and salivary gland [34].

LRP1B is a very large human gene (1,9 Mb), located at 2q22.1 close to the fragile site, FRA2K, at 2q22.3 [36]. Many large genes residing within unstable chromosomal regions are highly evolutionarily conserved, and in general are not traditional mutational targets; however, genomic alterations can occur due to fragile site instability and contribute to diseases, including a variety of cancers [37]. Furthermore, there are important potential linkages between such genomic alterations and neurological development or neurodegeneration, for e.g. CNTNAP2 (2,3 Mb) localized within FRA7I at 7q35 found disrupted in a family with Gilles de la Tourette syndrome [38], and PARK2 (1.3 Mb) mutated in autosomal recessive juvenile Parkinson disease and located in the active center of FRA6E at 6q26 [39].

Fragile sites are understood to be specific loci that preferentially exhibit gaps and breaks in metaphase chromosomes following partial inhibition of DNA synthesis, and their break-prone areas are almost equally distributed along chromosomes [36, 40]. Human chromosome 2 has the highest number of fragile sites, with twenty one break-prone regions spaced at an average distance of 11.52 Mb [36]. The deletion studied in this report is placed at 2q22.1q22.3, overlapping FRA2K (2q22.3) and preceeded by FRA2F at 2q21.3. This is in line with the fact that regions of chromosomal instability at or near fragile sites are hot-spots for deletions and other alterations [41].

The fragile site neighboring 2q22.1q22.3 may have facilitated the chromosomal aberration in our patient including the entire LRP1B gene region. Moreover, a haploinsufficiency rank of 13.8% was recently established for this gene, just above the 0–10% range indicating a high likelihood of exhibiting haploinsufficiency [17]. If LRP1B is haploinsufficient in our patient, and considering its biological function within the central nervous system, it is tempting to speculate on the participation of this gene in the patient’s observed cognitive impairment. In addition, the presence of SNP variant rs2890652 (142,676,401) in LRP1B has been associated with BMI by genome wide association analysis [42]. While it is clear that correlation with potentially functional variants does not prove that these variants are causal, they can provide initial clues into which genes might be prioritized in further studies [42]. Consequently, LRP1B should be the subject of further studies to assign its relationship with BMI. The clinical management for hypertension and BMI in our patient at the age of 17 years included the use of an angiotensin-converting enzyme inhibitor and a vigilant diet.

Conclusion

Here we describe a patient presenting severe ID/MR, autism spectrum disorder, dysmorphism and congenital malformations, with episodes of high blood pressure associated with high levels of BMI. A whole-genome aCGH screening revealed an approximate 6 Mb de novo deletion, and a review of the literature provides indications of a new contiguous gene syndrome located in 2q22.1 to 2q22.3.

Methods

Peripheral blood chromosome analysis at the 550 G-band level was performed applying standard cytogenetic procedures. Molecular testing for FMR1 and FMR2 genes was performed [43, 44]; and the subtelomeric ToTel Vysion panel of probes (Abbott–Vysis) was also done. DNA from the patient was isolated from lymphocytes according to standard protocols and was subjected to aCGH analysis [Human Whole-Genome CGH; NimbleGen Systems, Madison, WI] to evaluate the presence of pathogenic copy number changes. The platform contained 385.000 oligonucleotides at a median spacing of 6 kb. The data was analyzed with the NimbleGen SignalMap v.1.9 software. Fluorescence in situ hybridization (FISH) using standard protocols with the following BAC clones as probes were used to confirm the deletion: RP11-112 N16, RP11-731 F1, RP11-597P14, RP11-231E19, RP11-137 J9, RP11-432O12, RP11-15D9, RP11-164E7, RP11-64O2, RP11-58 K7 (Table 2) [15, 16].

Urinary organic acids were analyzed to evaluate the metabolic pathway of tryptophan once the KYNU gene was found to be deleted inside the 2q22 region (Table 1). This biochemical analysis was performed by high-resolution gas chromatography coupled to mass spectrometry (Agilent 5975 C, HP-5).

The family consented to participate in the study, which was approved by the Brazilian Ethical Committee Board.

Consent

Written informed consent was obtained from the parents of the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

CARS: 

Childhood Autism Rating Scale

FISH: 

Fluorescence in situ hybridization

ID/MR: 

Intellectual disability/Mental retardation

ISCN: 

International system for human cytogenetic nomenclature

aCGH: 

array-comparative genomic hybridization

BMI: 

Body Mass Index

MWS: 

Mowatt Wilson Syndrome

HD: 

Hirschprung disease.

Declarations

Acknowledgements

We are thankful for the patient’s family collaboration in this study, to Dr. Marcia Pimentel from SERVGEN, UERJ, for her kind help to allow us to use their molecular biology laboratory to perform FMR1 and FMR2 analysis. This work was partially supported by Brazilian grants: MVM received scholarships from CAPES (BEX:3692-05-1) and CNPq/FIOCRUZ (170060/2010-1) and JCLJr was granted by CNPq (Edital 061/2008; # 490754/2008-2). U19AI067769 grant (NR) from UCLA. Supported in part by the BMBF/DLR BRA 09/020.

Authors’ Affiliations

(1)
Instituto Fernandes Figueira, IFF/FIOCRUZ, Departamento de Genética Médica
(2)
Faculdade de Ciências Médicas, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, UERJ
(3)
Laboratório de Erros Inatos do Metabolismo, Departamento de Bioquímica, Instituto de Quimica, Universidade Federal do Rio de Janeiro, UFRJ
(4)
Chambon Laboratory for Molecular Diagnostics (member of the Synlab Czech laboratory group)
(5)
Institute of Human Genetics, Jena University Hospital, Friedrich Schiller University
(6)
Department of Pathology and Lab Medicine, The David Geffen School of Medicine at UCLA

References

  1. Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S: Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil 2008, 32(2):419–436.View Article
  2. Celep F, Sonmez FM, Karaguzel A: Chromosomal abnormalities in 457 Turkish patients with MCA/MR. Turk J Pediatr 2006, 48(2):130–134.PubMed
  3. Xu J, Chen Z: Advances in molecular cytogenetics for the evaluation of mental retardation. Am J Med Genet C Semin Med Genet 2003, 117C(1):15–24. 10.1002/ajmg.c.10016View ArticlePubMed
  4. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ, Watson MS, Martin CL, Ledbetter DH: Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010, 86: 749–764. 10.1016/j.ajhg.2010.04.006PubMed CentralView ArticlePubMed
  5. Mulatinho M, Llerena J, Leren TP, Rao PN, Quintero-Rivera F: Deletion (1)(p32.2-p32.3) detected by array-CGH in a patient with developmental delay/mental retardation, dysmorphic features and low cholesterol: a new microdeletion syndrome? Am J Med Genet A 2008, 146A(17):2284–2290. 10.1002/ajmg.a.32454View ArticlePubMed
  6. Slavotinek AM: Novel microdeletion syndromes detected by chromosome microarrays. Hum Genet 2008, 124(1):1–17. 10.1007/s00439-008-0513-9View ArticlePubMed
  7. Ballif BC, Theisen A, McDonald-McGinn DM, Zackai EH, Hersh JH, Bejjani BA, Shaffer LG: Identification of a previously unrecognized microdeletion syndrome of 16q11.2q12.2. Clin Genet 2008, 74(5):469–475. 10.1111/j.1399-0004.2008.01094.xView ArticlePubMed
  8. Park SJ, Jung EH, Ryu RS, Kang HW, Ko JM, Kim HJ, Cheon CK, Hwang SH, Kang HY: Clinical implementation of whole-genome array CGH as a first-tier test in 5080 pre and postnatal cases. Mol Cytogenet 2011, 4: 12. 10.1186/1755-8166-4-12PubMed CentralView ArticlePubMed
  9. OMIM. Online Mendelian Inheritance in Man http://​www.​ncbi.​nlm.​nih.​gov/​omim/​, OMIM. Online Mendelian Inheritance in Man http://​www.​ncbi.​nlm.​nih.​gov/​omim/​
  10. Mowat DR, Croaker GD, Cass DT, Kerr BA, Chaitow J, Ades LC, Chia NL, Wilson MJ: Hirschsprung disease, microcephaly, mental retardation, and characteristic facial features: delineation of a new syndrome and identification of a locus at chromosome 2q22-q23. J Med Genet 1998, 35(8):617–623. 10.1136/jmg.35.8.617PubMed CentralView ArticlePubMed
  11. Amiel J, Lyonnet S: Hirschsprung disease, associated syndromes, and genetics: a review. J Med Genet 2001, 38(11):729–739. 10.1136/jmg.38.11.729PubMed CentralView ArticlePubMed
  12. Zweier C, Albrecht B, Mitulla B, Behrens R, Beese M, Gillessen-Kaesbach G, Rott HD, Rauch A: “Mowat-Wilson” syndrome with and without Hirschsprung disease is a distinct, recognizable multiple congenital anomalies-mental retardation syndrome caused by mutations in the zinc finger homeo box 1B gene. Am J Med Genet 2002, 108(3):177–181. 10.1002/ajmg.10226View ArticlePubMed
  13. Zweier C, Temple IK, Beemer F, Zackai E, Lerman-Sagie T, Weschke B, Anderson CE, Rauch A: Characterisation of deletions of the ZFHX1B region and genotype-phenotype analysis in Mowat-Wilson syndrome. J Med Genet 2003, 40(8):601–605. 10.1136/jmg.40.8.601PubMed CentralView ArticlePubMed
  14. Database of Genomic Variants. Genomic Variants in Human Genome GRCh 37:Feb.2009 (hg 19) http://​projects.​tcag.​ca/​cgi-bin/​variation/​gbrowse/​hg19/​, Database of Genomic Variants. Genomic Variants in Human Genome GRCh 37:Feb.2009 (hg 19) http://​projects.​tcag.​ca/​cgi-bin/​variation/​gbrowse/​hg19/​
  15. UCSC GENOME BIOINFORMATICS genome.ucsc.edu
  16. CLONE DB http://​www.​ncbi.​nlm.​nih.​gov/​clone/​, CLONE DB http://​www.​ncbi.​nlm.​nih.​gov/​clone/​
  17. DECIPHER database decipher.sanger.ac.uk
  18. Hoffer MJ, Hilhorst-Hofstee Y, Knijnenburg J, Hansson KB, Engelberts AC, Laan LA, Bakker E, Rosenberg C: A 6 Mb deletion in band 2q22 due to a complex chromosome rearrangement associated with severe psychomotor retardation, microcephaly and distinctive dysmorphic facial features. Eur J Med Genet 2007, 50(2):149–154. 10.1016/j.ejmg.2006.11.004View ArticlePubMed
  19. Smigiel R, Szafranska A, Czyzewska M, Rauch A, Zweier C, Patkowski D: Severe clinical course of Hirschsprung disease in a Mowat-Wilson syndrome patient. J Appl Genet 2010, 51(1):111–113. 10.1007/BF03195718View ArticlePubMed
  20. Seoh ML, Ng CH, Yong J, Lim L, Leung T: ArhGAP15, a novel human RacGAP protein with GTPase binding property. FEBS Lett 2003, 539(1–3):131–137.View ArticlePubMed
  21. Zhao E, Li Y, Fu X, Zhang JY, Zeng H, Zeng L, Lin Y, Chen J, Yin G, Qian J, Ying K, Xie Y, Zhao RC, Mao YM: Cloning and expression of human GTDC1 gene (glycosyltransferase-like domain containing 1) from human fetal library. DNA Cell Biol 2004, 23(3):183–187. 10.1089/104454904322964788View ArticlePubMed
  22. Christensen M, Duno M, Lund AM, Skovby F, Christensen E: Xanthurenic aciduria due to a mutation in KYNU encoding kynureninase. J Inherit Metab Dis 2007, 30(2):248–255. 10.1007/s10545-007-0396-2View ArticlePubMed
  23. Beleza-Meireles A, Lundberg F, Lagerstedt K, Zhou X, Omrani D, Frisen L, Nordenskjold A: FGFR2, FGF8, FGF10 and BMP7 as candidate genes for hypospadias. Eur J Hum Genet 2007, 15(4):405–410. 10.1038/sj.ejhg.5201777View ArticlePubMed
  24. Grati FR, Turolla L, D’Ajello P, Ruggeri A, Miozzo M, Bracalente G, Baldo D, Laurino L, Boldorini R, Frate E and others: Chromosome 11 segmental paternal isodisomy in amniocytes from two fetuses with omphalocoele: new highlights on phenotype-genotype correlations in Beckwith-Wiedemann syndrome. J Med Genet 2007, 44(4):257–263. 10.1136/jmg.2006.046854PubMed CentralView ArticlePubMed
  25. Laitinen EM, Tommiska J, Virtanen HE, Oehlandt H, Koivu R, Vaaralahti K, Toppari J, Raivio T: Isolated cryptorchidism: no evidence for involvement of genes underlying isolated hypogonadotropic hypogonadism. Mol Cell Endocrinol 2011, 341(1–2):35–38.View ArticlePubMed
  26. Zhang Y, Zhang KX, He X, Yuan WT, Wang GL, Mao SY, Gao PJ, Huang W, Zhu DL: A polymorphism of kynureninase gene in a hypertensive candidate chromosomal region is associated with essential hypertension. Zhonghua Xin Xue Guan Bing Za Zhi 2005, 33(7):588–591.PubMed
  27. Mizutani K, Sugimoto K, Okuda T, Katsuya T, Miyata T, Tanabe T, Higaki J, Ogihara T, Yamori Y, Tsujita Y, Tago N, Iwai N: Kynureninase is a novel candidate gene for hypertension in spontaneously hypertensive rats. Hypertens Res 2002, 25(1):135–140. 10.1291/hypres.25.135View ArticlePubMed
  28. Kwok JB, Kapoor R, Gotoda T, Iwamoto Y, Iizuka Y, Yamada N, Isaacs KE, Kushwaha VV, Church WB, Schofield PR, Kapoor V: A missense mutation in kynurenine aminotransferase-1 in spontaneously hypertensive rats. J Biol Chem 2002, 277(39):35779–35782. 10.1074/jbc.C200303200View ArticlePubMed
  29. Komrower GM, Wilson V, Clamp JR, Westall RG: Hydroxykynureninuria: a Case of Abnormal Tryptophan Metabolism Probably Due to a Deficiency of Kynureninase. Arch Dis Child 1964, 39: 250–256. 10.1136/adc.39.205.250PubMed CentralView ArticlePubMed
  30. Wang Y, O’Connell JR, McArdle PF, Wade JB, Dorff SE, Shah SJ, Shi X, Pan L, Rampersaud E, Shen H, Kim JD, Subramanya AR, Steinle NI, Parsa A, Ober CC, Welling PA, Chakravarti A, Weder AB, Cooper RS, Mitchell BD, Shuldiner AR, Chang YP: From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci U S A 2009, 106(1):226–231. 10.1073/pnas.0808358106PubMed CentralView ArticlePubMed
  31. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC, Johnson AD, Aspelund T, Aulchenko Y, Lumley T, Kottgen A, Vasan RS, Rivadeneira F, Eiriksdottir G, Guo X, Arking DE, Mitchell GF, Mattace-Raso FU, Smith AV, Taylor K, Scharpf RB, Hwang SJ, Sijbrands EJ, Bis J, Harris TB, Ganesh SK, O’Donnell CJ, Hofman A, Rotter JI, Coresh J, Benjamin EJ, Uitterlinden AG, Heiss G, Fox CS, Witteman JC, Boerwinkle E, Wang J, Gudnason V, Larson MG, Chakravarti A, Psaty BM, van Duijn CM: Genome-wide association study of blood pressure and hypertension. Nat Genet 2009, 41(6):677–687. 10.1038/ng.384PubMed CentralView ArticlePubMed
  32. Aberg K, Dai F, Viali S, Tuitele J, Sun G, Indugula SR, Deka R, Weeks DE, McGarvey ST: Suggestive linkage detected for blood pressure related traits on 2q and 22q in the population on the Samoan islands. BMC Med Genet 2009, 10: 107. 10.1186/1471-2350-10-107PubMed CentralView ArticlePubMed
  33. Cam JA, Zerbinatti CV, Knisely JM, Hecimovic S, Li Y, Bu G: The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. J Biol Chem 2004, 279(28):29639–29646. 10.1074/jbc.M313893200View ArticlePubMed
  34. Liu CX, Li Y, Obermoeller-McCormick LM, Schwartz AL, Bu G: The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein. J Biol Chem 2001, 276(31):28889–28896. 10.1074/jbc.M102727200View ArticlePubMed
  35. Liu CX, Musco S, Lisitsina NM, Yaklichkin SY, Lisitsyn NA: Genomic organization of a new candidate tumor suppressor gene, LRP1B. Genomics 2000, 69(2):271–274. 10.1006/geno.2000.6331View ArticlePubMed
  36. Mrasek K, Schoder C, Teichmann AC, Behr K, Franze B, Wilhelm K, Blaurock N, Claussen U, Liehr T, Weise A: Global screening and extended nomenclature for 230 aphidicolin-inducible fragile sites, including 61 yet unreported ones. Int J Oncol 2010, 36(4):929–940.PubMed
  37. Smith DI, McAvoy S, Zhu Y, Perez DS: Large common fragile site genes and cancer. Semin Cancer Biol 2007, 17(1):31–41. 10.1016/j.semcancer.2006.10.003View ArticlePubMed
  38. Verkerk AJ, Mathews CA, Joosse M, Eussen BH, Heutink P, Oostra BA: CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder. Genomics 2003, 82(1):1–9. 10.1016/S0888-7543(03)00097-1View ArticlePubMed
  39. Denison SR, Callahan G, Becker NA, Phillips LA, Smith DI: Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer 2003, 38(1):40–52. 10.1002/gcc.10236View ArticlePubMed
  40. Durkin SG, Glover TW: Chromosome fragile sites. Annu Rev Genet 2007, 41: 169–192. 10.1146/annurev.genet.41.042007.165900View ArticlePubMed
  41. Lukusa T, Fryns JP: Human chromosome fragility. Biochim Biophys Acta 2008, 1779(1):3–16.View ArticlePubMed
  42. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Allen HL, Lindgren CM, Luan J, Magi R, Randall JC, Vedantam S, Winkler TW, Qi L, Workalemahu T, Heid IM, Steinthorsdottir V, Stringham HM, Weedon MN, Wheeler E, Wood AR, Ferreira T, Weyant RJ, Segre AV, Estrada K, Liang L, Nemesh J, Park JH, Gustafsson S, Kilpelainen TO, Yang J, Bouatia-Naji N, Esko T, Feitosa MF, Kutalik Z, Mangino M, Raychaudhuri S, Scherag A, Smith AV, Welch R, Zhao JH, Aben KK, Absher DM, Amin N, Dixon AL, Fisher E, Glazer NL, Goddard ME, Heard-Costa NL, Hoesel V, Hottenga JJ, Johansson A, Johnson T, Ketkar S, Lamina C, Li S, Moffatt MF, Myers RH, Narisu N, Perry JR, Peters MJ, Preuss M, Ripatti S, Rivadeneira F, Sandholt C, Scott LJ, Timpson NJ, Tyrer JP, van Wingerden S, Watanabe RM, White CC, Wiklund F, Barlassina C, Chasman DI, Cooper MN, Jansson JO, Lawrence RW, Pellikka N, Prokopenko I, Shi J, Thiering E, Alavere H, Alibrandi MT, Almgren P, Arnold AM, Aspelund T, Atwood LD, Balkau B, Balmforth AJ, Bennett AJ, Ben-Shlomo Y, Bergman RN, Bergmann S, Biebermann H, Blakemore AI, Boes T, Bonnycastle LL, Bornstein SR, Brown MJ, Buchanan TA, et al.: Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010, 42(11):937–948. 10.1038/ng.686PubMed CentralView ArticlePubMed
  43. Haddad LA, Mingroni-Netto RC, Vianna-Morgante AM, Pena SD: A PCR-based test suitable for screening for fragile X syndrome among mentally retarded males. Hum Genet 1996, 97(6):808–812. 10.1007/BF02346194View ArticlePubMed
  44. Santos CB, Costa Lima MA, Pimentel MM: A new PCR assay useful for screening of FRAXE/FMR2 mental impairment among males. Hum Mutat 2001, 18(2):157–162. 10.1002/humu.1165View ArticlePubMed

Copyright

© Mulatinho et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.